Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Non-Current Assets (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Other Non-Current Assets for 8 consecutive years, with $427000.0 as the latest value for Q3 2022.

  • Quarterly Other Non-Current Assets fell 42.76% to $427000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $427000.0 through Sep 2022, down 42.76% year-over-year, with the annual reading at $1.3 million for FY2021, 50.72% down from the prior year.
  • Other Non-Current Assets hit $427000.0 in Q3 2022 for Aptevo Therapeutics, down from $546000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $12.4 million in Q2 2018 to a low of $400000.0 in Q1 2018.
  • Historically, Other Non-Current Assets has averaged $3.0 million across 5 years, with a median of $1.2 million in 2019.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 3011.75% in 2018 and later plummeted 89.97% in 2019.
  • Year by year, Other Non-Current Assets stood at $7.4 million in 2018, then rose by 0.67% to $7.5 million in 2019, then plummeted by 65.92% to $2.6 million in 2020, then tumbled by 50.72% to $1.3 million in 2021, then tumbled by 66.08% to $427000.0 in 2022.
  • Business Quant data shows Other Non-Current Assets for APVO at $427000.0 in Q3 2022, $546000.0 in Q2 2022, and $1.3 million in Q1 2022.